Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 73

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 73
---
 laws
in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside
the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.
Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further,
may export otherwise infringing products to certain territories where we have patent protection, but enforcement is not as strong as that
in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective
or sufficient to prevent them from competing. Many of our patent families remain at various stages of application in multiple global territories
which have not yet been granted. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions
in our portfolio prior to applicable deadlines. We may decide to abandon national and regional patent applications before they are granted.
The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the
same family may issue as patents in some jurisdictions, such as in the United States, but may issue as patents with claims of different
scope or may be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection
may vary for the same product or technology. For example, certain jurisdictions do not allow for patent protection with respect to method
of treatment.

Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protections,
particularly those relating to biopharmaceutical products. This difficulty with enforcing patents could make it difficult for us to stop
the infringement of our patents or marketing of competing products otherwise generally in violation of our proprietary rights. Proceedings
to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, put our patent applications at risk
of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the
damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop